预约演示
更新于：2026-06-14
Furosemide
呋塞米
更新于：2026-06-14
概要
基本信息
简介Furosemide是属于NKCC2抑制剂的小分子药物，可阻止肾脏Henle升支中的钠-钾-氯共同转运体的活性。这种机制导致尿液产生增加，钠、氯和钾离子的重吸收减少，从而减少了体液潴留和血压。Furosemide主要被批准用于治疗水肿和高血压，通常还与充血性心力衰竭、肝硬化和肾功能障碍等情况相关。Furosemide于1964年1月首次获批，由跨国制药公司赛诺菲生产。 |
药物类型 小分子化药 |
别名 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid、4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid、4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid + [25] |
靶点 |
作用方式 抑制剂 |
作用机制 NKCC2抑制剂(钠钾氯协同转运蛋白-2抑制剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C12H11ClN2O5S |
InChIKeyZZUFCTLCJUWOSV-UHFFFAOYSA-N |
CAS号54-31-9 |
关联
405
项与 呋塞米 相关的临床试验NCT07018297
Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure: A Cluster-Randomized Crossover Non-Inferiority Trial
NCT07593612
TACTIC-HF: Thiazide or Acetazolamide Combination Versus Intravenous Furosemide in Ambulatory Worsening Heart Failure - a Randomized Crossover Trial
NCT07167862
Optimizing Preeclampsia Postpartum With Point-of-Care Ultrasound: A Pilot Prospective Cohort Study
100 项与 呋塞米 相关的临床结果
登录后查看更多信息
100 项与 呋塞米 相关的转化医学
登录后查看更多信息
100 项与 呋塞米 相关的专利（医药）
登录后查看更多信息
17,755
项与 呋塞米 相关的文献（医药）2026-12-31Journal of Maternal-Fetal & Neonatal Medicine
Transient conductive hearing loss as a notable and rare manifestation of preeclampsia: a case report
Article
作者: Chen, Xiuying ; Jin, Linna ; Zhao, Baihui
OBJECTIVE:
To report a case of transient conductive hearing loss secondary to secretory otitis media (SOM) in a patient with preeclampsia, highlight its unique pathophysiological link, and emphasize the importance of recognizing this potential complication.
CASE PRESENTATION:
Preeclampsia is a severe, pregnancy-specific multisystem disorder characterized by new-onset hypertension and proteinuria after 20 weeks of gestation. While endothelial dysfunction and vasospasm are central to its pathophysiology, its clinical manifestations are diverse. Auditory dysfunction, particularly conductive hearing loss, is infrequently reported. We present a case of a 25-year-old gravida 2, para 0 woman diagnosed with preeclampsia at 33 weeks of gestation. She had persistent proteinuria (24-hour urinary protein 1244.7 mg), unstable hypertension (148-165/95-107mmHg) managed with labetalol (100 mg every 8 h, suboptimal adherence), and gestational diabetes. She had no prior history of ear disease, trauma, or ototoxic medication use.At 35w5d gestation, the patient developed sudden bilateral hearing loss, accompanied by mild chest tightness and an elevated brain natriuretic peptide (BNP) level (346.1 pg/ml). Otolaryngology consultation was performed, and otoendoscopic examination revealed bilateral intratympanic fluid. Pure tone audiometry confirmed bilateral conductive hearing loss with significant air-bone gaps (left 30 dB, right 13 dB). Bone conduction thresholds were within normal limits (left 15 dB, right 16 dB), ruling out sensorineural hearing loss. Acoustic immittance audiometry showed bilateral B-type tympanograms, indicative of middle ear effusion. Alternative causes of conductive hearing loss (e.g. upper respiratory infection-related eustachian tube dysfunction, barotrauma, tympanic membrane pathology, middle ear mass) were excluded through clinical evaluation, negative inflammatory markers (C-reactive protein: <0.5 mg/l, white blood cell count: 12.9 × 10^9), and absence of relevant symptoms. Given her deteriorating condition, an emergent Cesarean section was performed at 36 weeks of gestation, delivering a healthy male infant. Postoperatively, supportive management with combined diuretics (furosemide and spironolactone) led to rapid and complete resolution of her hearing deficits within three days. She was discharged on continued antihypertensive therapy and was well at one-month follow-up.
CONCLUSION:
Transient conductive hearing loss due to SOM is a rare manifestation of preeclampsia, likely driven by hypertension-induced increased vascular permeability and altered fluid dynamics. Severe proteinuria may exacerbate systemic fluid imbalance, contributing to middle ear effusion. Early recognition via audiometric and tympanometric evaluation, exclusion of alternative etiologies, and targeted management (e.g. fluid overload reduction) can ensure prompt recovery and improve maternal outcomes. Early recognition and management can improve maternal outcomes by addressing fluid dysregulation and potentially preventing further complications.
2026-09-01AMERICAN HEART JOURNAL
Vasodilation, loop diuretics, or their combination in acute heart failure: Rationale and design of the randomized placebo-controlled DECONGEST-AHF trial
Article
作者: Thomsen, Jakob Hartvig ; Jakobsen, Janus Christian ; Seven, Ekim ; Folke, Fredrik ; Thune, Jens Jakob ; Lukoschewitz, Jasmin Dam ; Grand, Johannes ; Taraldsen, Ida Arentz ; Nielsen, Søren Junge ; Mottlau, Rasmus Gregersen ; Tonning, Sandra ; Lindholm, Matias Greve ; Haastrup, Simone Bonde ; El Caidi, Nora Olsen ; Olesen, Anne Sophie Overgaard ; Doleman, Brett ; Najim, Ahmed ; Hove, Jens Dahlgaard ; Nygaard, Hanne
BACKGROUND:
Acute heart failure is the leading cause of hospitalization in older adults and carries a high risk of short-term death or readmission. Initial treatment involves intravenous loop diuretics, often combined with vasodilators, despite limited evidence. The individual and combined effects of loop diuretics and vasodilators have never been directly compared during the initial emergency phase, as previous studies have included patients after early stabilization, leaving the optimal first-line treatment unknown.
STUDY DESIGN:
DECONGEST-AHF is a pragmatic, multicenter, randomized, double-blinded, placebo-controlled trial evaluating early treatment strategies in patients with suspected acute heart failure. Patients are included no later than 3 hours after emergency department arrival. Inclusion criteria are acute dyspnea, clinical signs of congestion, oxygen saturation <94% or need for oxygen therapy, and systolic blood pressure ≥100 mmHg. Patients are randomized (1:1:1) to receive intravenous furosemide, intravenous isosorbide dinitrate, or both as initial in-hospital treatment. The primary outcome is days alive and outside of the hospital at 30 days. The trial will enroll 1,041 patients across 5 Danish hospitals.
DISCUSSION:
By initiating treatment during the hyperacute phase and applying a blinded and placebo-controlled design, we aim to clarify the individual and combined effects of 2 widely used therapies. The use of emergency consent procedures enables the inclusion of a real-world patient population, including patients who are often excluded from clinical trials. This approach ensures broad generalizability and reflects routine emergency care. Findings from DECONGEST-AHF may improve early management of patients with acute heart failure.
TRIAL REGISTRATION:
ClinicalTrials.gov identifier:(NCT05276219).
2026-08-01Journal of Veterinary Cardiology
Recurrent transient myocardial thickening and congestive heart failure in a cat
Article
作者: Chapel, E ; Zhang, M
A five-year-old female spayed domestic shorthair cat presented for acute onset respiratory distress. Thoracic radiographs and echocardiography revealed left-sided congestive heart failure and left ventricular thickening with left atrial dilation, respectively. The cat was treated with furosemide, clopidogrel, and ondansetron. Re-evaluation one year later revealed complete reverse remodeling with normalization of the left ventricle and left atrial size on echocardiography. Medical therapy was discontinued. Approximately two years after the initial presentation, the cat presented again for acute onset respiratory distress. Thoracic radiographs and echocardiography again revealed left-sided congestive heart failure and left atrial dilation, with thickening of the interventricular septum and left ventricular posterior wall. Cardiac troponin I was elevated and progressively increased over the first 24 hours, then decreased and ultimately normalized following treatment with furosemide, clindamycin, enrofloxacin, doxycycline, and clopidogrel. Infectious disease testing did not reveal an underlying cause. Re-evaluation one year later again revealed cardiac normalization on echocardiography. Here, we report a case of recurrent transient myocardial thickening in a cat.
100 项与 呋塞米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性肾病 | 美国 | 2025-03-06 | |
| 肾病综合征 | 美国 | 2025-03-06 | |
| 慢性心力衰竭 | 美国 | 2022-10-07 | |
| 心源性水肿 | 日本 | 2002-10-31 | |
| 心脏衰竭 | 日本 | 2002-10-31 | |
| 急性肺水肿 | 澳大利亚 | 1991-08-01 | |
| 脑水肿 | 澳大利亚 | 1991-08-01 | |
| 少尿 | 日本 | 1981-09-01 | |
| 水肿 | 日本 | 1965-05-01 | |
| 高血压 | 日本 | 1965-05-01 | |
| 经前综合征 | 日本 | 1965-05-01 | |
| 泌尿结石 | 日本 | 1965-05-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性失代偿性心力衰竭 | 临床3期 | 美国 | 2016-02-01 | |
| 音量过载 | 临床2期 | 荷兰 | 2014-12-01 | |
| 终末期肾脏病 | 临床1期 | 加拿大 | 2012-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 1,041 | 範簾鹽糧選鹽淵網廠築(顧餘憲鑰窪齋壓糧構構) = 網淵構顧顧繭範餘鑰憲 艱廠顧夢鏇鏇鹽醖觸築 (艱淵憲壓廠齋製築顧齋, 23.4 ~ 31.7) | 积极 | 2026-09-01 | |||
临床2期 | 170 | 艱築鬱構壓構簾簾齋糧(構製繭蓋鬱鬱廠醖夢窪) = 艱夢願觸廠繭簾夢壓製 淵夢獵膚簾鏇網選選顧 (襯遞遞夢遞艱築遞積網, 13.0) 更多 | 积极 | 2026-01-12 | |||
夢淵艱壓窪夢壓鏇鏇夢(襯遞積醖窪廠憲簾顧鑰) = 蓋積顧鹹夢廠廠夢願顧 願齋範蓋鏇齋選憲衊獵 (鑰壓憲網鑰繭鑰膚鬱廠 ) | |||||||
临床1期 | - | 32 | Dabigatran-etexilate (Dabigatran-etexilate (R)) | 鬱範窪鹹範鏇艱製齋壓(遞網鹹積糧衊遞憲鏇膚) = 積夢簾鏇獵膚蓋範製膚 憲蓋憲觸鑰憲醖廠鑰齋 (襯憲鹽繭齋簾膚選願範, NA) 更多 | - | 2026-01-09 | |
(Zongertinib and dabigatran-etexilate (T)) | 鬱範窪鹹範鏇艱製齋壓(遞網鹹積糧衊遞憲鏇膚) = 選蓋淵夢製顧積蓋鬱齋 憲蓋憲觸鑰憲醖廠鑰齋 (襯憲鹽繭齋簾膚選願範, NA) 更多 | ||||||
临床3期 | 2,973 | (Torsemide) | 醖鹹網憲築獵網築蓋餘 = 襯鹹糧積積顧願顧遞膚 衊襯構壓餘簾膚齋觸鬱 (鬱襯觸艱鹹餘構鹹衊襯, 齋鑰膚鏇齋壓淵鬱齋齋 ~ 鏇淵鑰顧鏇衊衊齋遞積) 更多 | - | 2025-10-16 | ||
(Furosemide) | 醖鹹網憲築獵網築蓋餘 = 鏇鑰築築鏇襯構憲選蓋 衊襯構壓餘簾膚齋觸鬱 (鬱襯觸艱鹹餘構鹹衊襯, 獵壓選獵衊壓窪衊憲蓋 ~ 糧鑰艱膚餘簾構簾夢廠) 更多 | ||||||
临床2期 | 70 | (? 12 BAN-ADHF, Furoscix) | 齋製齋糧鬱選餘製遞壓(衊餘艱鹽願築製糧顧範) = 廠醖鑰遞製鑰鹹艱窪衊 鑰廠窪襯築艱顧願鑰糧 (鏇鬱網繭夢憲願願觸遞, 廠鏇憲淵醖築製醖餘齋 ~ 願夢蓋餘醖獵廠願膚餘) 更多 | - | 2025-07-16 | ||
(<= 11 BAN-ADHF, Furoscix) | 齋製齋糧鬱選餘製遞壓(衊餘艱鹽願築製糧顧範) = 餘繭製選獵壓獵淵網糧 鑰廠窪襯築艱顧願鑰糧 (鏇鬱網繭夢憲願願觸遞, 膚鹹醖製積蓋壓顧淵齋 ~ 衊範壓範獵鹽鬱夢糧鑰) 更多 | ||||||
临床4期 | 21 | (Furosemide (Lasix) Alone) | 範齋夢鏇廠鹹衊構餘顧(夢衊範壓餘鹽構網憲憲) = 餘艱顧鑰餘鏇構蓋顧觸 鹽鏇願窪衊願顧蓋鏇壓 (觸淵窪獵廠憲製餘壓窪, 遞構繭繭鹹艱鑰觸製醖 ~ 齋遞顧餘艱蓋鹽鑰憲鬱) 更多 | - | 2025-05-09 | ||
Albumin Human+Furosemide Injection (Combination of Furosemide (Lasix) and Albumin) | 範齋夢鏇廠鹹衊構餘顧(夢衊範壓餘鹽構網憲憲) = 艱膚範糧遞積餘膚廠顧 鹽鏇願窪衊願顧蓋鏇壓 (觸淵窪獵廠憲製餘壓窪, 構網範膚艱繭廠廠獵選 ~ 蓋製願構醖糧遞鏇淵鬱) 更多 | ||||||
早期临床1期 | 60 | 窪鏇鏇範淵齋網窪繭淵(鑰選遞廠醖淵壓觸窪願): P-Value = ≤0.001 更多 | 积极 | 2025-04-01 | |||
Normal Saline (NS) flush | |||||||
临床3期 | 47 | (Furosemide) | 衊廠憲艱餘衊廠夢蓋壓 = 憲壓廠窪網簾鬱觸窪鑰 膚鏇鏇鹽鹽廠齋範顧夢 (窪襯積艱蓋蓋築艱積簾, 鬱衊醖鑰願獵鏇蓋膚範 ~ 艱蓋鹽鑰醖鏇觸鹽壓獵) 更多 | - | 2024-10-15 | ||
(Torsemide) | 衊廠憲艱餘衊廠夢蓋壓 = 鏇夢艱鏇願製鏇衊鏇齋 膚鏇鏇鹽鹽廠齋範顧夢 (窪襯積艱蓋蓋築艱積簾, 構鏇簾獵積觸積製壓蓋 ~ 構淵選廠餘膚遞鏇願獵) 更多 | ||||||
N/A | 8 | (Arm1- Furosemide and Hydrochlorothiazide Then Furosemide + Metolazone) | 繭遞窪築遞艱築觸願憲 = 廠襯觸鹽築觸網鏇餘襯 鏇窪顧獵夢醖範襯鏇積 (齋憲鬱憲衊繭構蓋蓋鹽, 繭憲簾願製顧積繭鹽夢 ~ 壓衊積選齋窪衊餘蓋築) 更多 | - | 2024-10-10 | ||
(Arm2-Furosemide and Metolazone Then Furosemide and Hydrochlorothiazide) | 繭遞窪築遞艱築觸願憲 = 繭壓觸鹹窪鏇襯構簾積 鏇窪顧獵夢醖範襯鏇積 (齋憲鬱憲衊繭構蓋蓋鹽, 廠築選壓鑰鏇鏇窪膚獵 ~ 網築構淵蓋遞鹽淵襯遞) 更多 | ||||||
临床1期 | - | - | SCP-111 Autoinjector | 齋壓網顧襯壓鹽艱繭製(廠蓋築夢膚鏇醖積襯觸) = 製齋觸築衊築餘壓壓積 範鑰鹽膚築願積壓膚鑰 (鬱製淵夢糧築廠壓鹽簾, 103.9 ~ 110.8) 更多 | 积极 | 2024-08-12 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用